SCHEMBL313640

SCHEMBL313640

C#Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.44
CES2 O00748 1/20 0.41
PTPN1 P18031 2/20 0.40
IDO1 P14902 2/20 0.37
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
ADRB1 P08588 1/20 0.33
MAPT P10636 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGAV P06756 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
KIF11 P52732 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
RPS6KA3 P51812 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17207304 0.84 TAS2R14 (0.39) ADRA2BADRA2CTAS2R14CES2PTPN1
SCHEMBL24780639 0.80 ADRA2B (0.37) ADRA2BADRA2CTAS2R14PTPN1IDO1
SCHEMBL20610195 0.78 ADRA2B (0.51) ADRA2BADRA2CTAS2R14CES2PTPN1
SCHEMBL6227551 0.78 CES2 (0.44) CES2IDO1ADRB1MAPTRAPGEF4
SCHEMBL29890941 0.77 PTPN1 (0.61) ADRA2BADRA2CTAS2R14CES2PTPN1
SCHEMBL933875 0.77 PTPN1 (0.61) ADRA2BADRA2CTAS2R14CES2PTPN1
SCHEMBL440959 0.76 CES2 (0.58) CES2IDO1ADRB1MAPTRAPGEF4
SCHEMBL20905128 0.75 IDO1 (0.44) ADRA2BADRA2CTAS2R14PTPN1IDO1
SCHEMBL20905127 0.75 IDO1 (0.44) ADRA2BADRA2CTAS2R14PTPN1IDO1
SCHEMBL11235815 0.75 ADRA2B (0.35) ADRA2BADRA2CTAS2R14PTPN1RAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157898-B1 CHEMICALLY CONVERTED CATALYSTS DOW GLOBAL TECHNOLOGIES LLC (US) 2026-04-29 EP claimed
CN-119395917-A Preparation method of anti-mode polymer stabilized cholesteric liquid crystal intelligent window with low energy consumption and high privacy 哈尔滨工业大学 2025-02-07 CN claimed
CN-115667328-B Catalyst for chemical conversion 陶氏环球技术有限责任公司 2024-11-08 CN claimed
CN-117646229-A Method for preparing ammonia by catalyzing NO through ultra-small copper nanoclusters 广州惠清环保技术有限公司 2024-03-05 CN claimed
CN-117624520-A Trifluoromethyl modified pyrenyl covalent organic framework material, and preparation method and application thereof 中国石油大学(华东) 2024-03-01 CN claimed
CN-116747905-A Preparation of ultra-small palladium nanocluster and application thereof in eliminating nitrate nitrogen in wastewater 广州惠清环保技术有限公司 2023-09-15 CN claimed
US-20230203218-A1 CHEMICALLY CONVERTED CATALYSTS DOW GLOBAL TECHNOLOGIES LLC (US) 2023-06-29 US claimed
CN-115322644-B Modified alkynyl polymer coating constructed in situ at interface and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2023-06-02 CN claimed
EP-4157898-A1 CHEMICALLY CONVERTED CATALYSTS Dow Global Technologies LLC (US) 2023-04-05 EP claimed
CN-115667328-A Catalyst for chemical conversion 陶氏环球技术有限责任公司 2023-01-31 CN claimed
CN-115322644-A Modified alkynyl polymer coating constructed in situ at interface and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2022-11-11 CN claimed
CN-114874088-A Acetylenic acid and preparation method thereof 中国科学院上海高等研究院 2022-08-09 CN claimed
WO-2021243158-A1 CHEMICALLY CONVERTED CATALYSTS DOW GLOBAL TECHNOLOGIES LLC (US) 2021-12-02 WO claimed
EP-3623394-A1 METALLACYCLOALKYLENE COMPLEXES AND USE FOR ALKYNE POLYMERIZATION TO CYCLIC POLYACETYLENES University of Florida Research Foundation, Inc. (US) 2020-03-18 EP claimed
EP-1337512-B1 (4-ACYLAMINOPIPERIDIN-1-YL) ACETAMIDES AS NEUROKININ ANTAGONISTS BOEHRINGER INGELHEIM PHARMA (DE) 2007-06-13 EP claimed
EP-4157898-B1 CHEMICALLY CONVERTED CATALYSTS DOW GLOBAL TECHNOLOGIES LLC (US) 2026-04-29 EP disclosed
US-12550608-B2 Organic light emitting diode and organic light emitting device including the same LG DISPLAY CO., LTD. (KR) 2026-02-10 US disclosed
EP-1149067-A1 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
US-6310247-B1 HAS APOPTOTIC ACTIVITY USEFUL FOR PROPHYLAXIS AND THERAPY OF CANCER HOFFMANN-LA ROCHE INC. 2001-10-30 US disclosed
WO-2000035856-A1 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12550608-B2 Organic light emitting diode and organic light emitting device including the same HCN1, HCN4, HCN2 ADRA2B 2282/4885ADRA2C 2227/4885TAS2R14 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.